Riviciclib

• Description :

  Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively[1][2]. Riviciclib shows antitumor activity on cisplatin-resistant cells[3].

• Product Name Alternative :

  P276-00 (free base)

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Riviciclib.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1C=C(C2=C(Cl)C=CC=C2)OC3=C([C@H]4[C@H](CO)N(C)CC4)C(O)=CC(O)=C13

• Molecular Formula :

  C21H20ClNO5

• Molecular Weight :

  401.84

• References & Citations :

  [1]Roskoski R Jr, Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.Pharmacol Res. 2016 May;107:249-275.|[2]Joshi KS, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6 (3) :918-25.|[3]Joshi KS, et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6 (3) :926-34.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  CDK1; CDK2; CDK4; CDK6; CDK9

• Citation 01 :

  Int J Mol Sci. 2022 Feb 24;23 (5) :2493.|Elife. 2020 Dec 7;9:e61405.|Pharmaceuticals (Basel) . 2024 Apr 29;17 (5) :569.

• CAS Number :

  [920113-02-6]